Cannabis offers exit ramp from alcohol, opioid addiction

Cannabis has been labeled a “gateway," but recent research shows marijuana may be more of an exit drug for people with addiction problems while also improving mental health.

A team from the University of British Columbia (UBC) published in Clinical Psychology Review examined past research and found marijuana can help individuals addicted to alcohol and opioids.

"Research suggests that people may be using cannabis as an exit drug to reduce the use of substances that are potentially more harmful, such as opioid pain medication," said lead investigator Zach Walsh, an associate professor of psychology at UBC.

In a systematic review of research done on the effect of medical cannabis on mental health, researchers have found that cannabis could help with symptoms associated with depression, PTSD and social anxiety. With the identification of proven positive effect of medical cannabis, Walsh hopes the stigma attached to it will dissolve.

"There is not currently a lot of clear guidance on how mental health professionals can best work with people who are using cannabis for medical purposes," says Walsh. "With the end of prohibition, telling people to simply stop using may no longer be as feasible an option. Knowing how to consider cannabis in the treatment equation will become a necessity."

By reviewing all current studies on medical cannabis and mental health, the review is one of the most inclusive studies on the subject. With tangible evidence in favor or medical cannabis and its benefits, and with 25 states and the District of Columbia, the full legalization of cannabis is just over the horizon. 

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.